Shares of Sanofi (NASDAQ:SNY) and Roche (OTCQX:RHHBY) were flat in European trading on Thursday after the EU pharma giants reaffirmed their full-year forecasts while reporting their respective Q1 2025 results.
France-based Sanofi (NASDAQ:SNY) said it continues to expect mid-to-high single-digit percentage growth in its sales and low double-digit growth in its earnings per share for 2025 on a forex-adjusted basis.
The Paris-based firm reported €9.9B ($11.3B) in sales for the quarter, exceeding the consensus by €120M with ~11% YoY growth thanks mainly to its Regeneron (REGN)-partnered asthma therapy Dupixent, which added €3.5B to the topline with ~20% YoY improvement.
Meanwhile, SNY’s RSV vaccine, Beyfortus, marketed with AstraZeneca (AZN), generated €284M in sales with ~56% YoY growth, helping the company’s vaccine business to expand by ~11% YoY with €1.3B in sales.
Sanofi’s (NASDAQ:SNY) business operating income, excluding one-time items, rose ~21% YoY to €2.9B thanks mainly to a 2.3 percentage point increase in gross margin, exceeding €2.7B projected by analysts, according to Reuters data.
As for rival Roche (OTCQX:RHHBY), the Swiss pharma giant recorded CHF 15.44B ($18.7B) in sales for the Jan-Mar quarter with ~7% YoY growth, modestly surpassing the analysts’ estimates of CHF 15.4B, per Reuters data.
The company’s Pharma segment added CHF 11.9B to the topline with ~9% growth, while its Diagnostics unit brought in CHF 3.5B, mostly unchanged from last year. RHHBY’s multiple sclerosis therapy Ocrevus, eye therapy Vabysmo, and hemophilia therapy Hemlibra drove the pharma expansion with ~6%, ~18%, and 11% growth, respectively.
The Basel-based company continues to expect a mid-single-digit range of growth and a high single-digit range of growth for its 2025 sales and core earnings per share on a forex-adjusted basis, respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.